Skip to content

Study · Non-randomized trial · 1994

5 results

Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis.

Eckford SD, Swami KS, Jackson SR, Abrams PH

British journal of urology1 Dec 1994Cited by 31 (Europe PMC)

PMID7827843 (opens in a new tab)DOI10.1111/j.1464-410x.1994.tb07116.x (opens in a new tab)PepBankPUB-07827843
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin significantly decreased nocturnal urinary frequency compared with placebo.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced night-time urination frequency compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturnal urinary frequency
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Urinary Function · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Desmopressin caused a significant decrease in nocturnal urinary frequency, nocturnal urinary volume and the percentage of total daily urine passed at night.
    2 context sentences
    Summary · context
    Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.
    Summary · context
    A two week placebo run-in, to establish normal voiding patterns, followed by a double-blind, placebo-controlled, cross-over study of 20 micrograms intranasal desmopressin at night-time was carried out.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin significantly decreased nocturnal urinary volume compared with placebo.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced night-time urine volume compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturnal urinary volume
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Urinary Function · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Desmopressin caused a significant decrease in nocturnal urinary frequency, nocturnal urinary volume and the percentage of total daily urine passed at night.
    2 context sentences
    Summary · context
    Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.
    Summary · context
    A two week placebo run-in, to establish normal voiding patterns, followed by a double-blind, placebo-controlled, cross-over study of 20 micrograms intranasal desmopressin at night-time was carried out.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin significantly decreased the percentage of daily urine passed at night compared with placebo.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced the proportion of urine passed at night compared with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreasePercentage of daily urine passed at night
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Urinary Function · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Desmopressin caused a significant decrease in nocturnal urinary frequency, nocturnal urinary volume and the percentage of total daily urine passed at night.
    2 context sentences
    Summary · context
    Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.
    Summary · context
    A two week placebo run-in, to establish normal voiding patterns, followed by a double-blind, placebo-controlled, cross-over study of 20 micrograms intranasal desmopressin at night-time was carried out.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis, plasma sodium did not fall significantly with desmopressin.

    In plain wordsIn patients with multiple sclerosis, blood sodium did not fall significantly with desmopressin.

    Peptide
    Desmopressin
    Outcome
    No significant changePlasma sodium
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was no significant fall in plasma sodium with desmopressin although there were two cases of asymptomatic hyponatraemia.
    2 context sentences
    Summary · context
    Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.
    Summary · context
    A two week placebo run-in, to establish normal voiding patterns, followed by a double-blind, placebo-controlled, cross-over study of 20 micrograms intranasal desmopressin at night-time was carried out.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis, two cases of asymptomatic hyponatraemia occurred with desmopressin.

    In plain wordsIn patients with multiple sclerosis, two patients developed low blood sodium without symptoms with desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableAsymptomatic hyponatraemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Measurements

    Cases
    2 cases
    asymptomatic hyponatraemia

    Source sentences

    Summary
    There was no significant fall in plasma sodium with desmopressin although there were two cases of asymptomatic hyponatraemia.
    2 context sentences
    Summary · context
    Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.
    Summary · context
    A two week placebo run-in, to establish normal voiding patterns, followed by a double-blind, placebo-controlled, cross-over study of 20 micrograms intranasal desmopressin at night-time was carried out.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.